nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—CYP1A1—kidney cancer	0.626	1	CbGaD
Thiabendazole—CYP1A1—Erlotinib—kidney cancer	0.0952	0.411	CbGbCtD
Thiabendazole—CYP1A2—Pazopanib—kidney cancer	0.0596	0.257	CbGbCtD
Thiabendazole—CYP1A2—Erlotinib—kidney cancer	0.0425	0.183	CbGbCtD
Thiabendazole—CYP1A2—Sorafenib—kidney cancer	0.0346	0.149	CbGbCtD
Thiabendazole—Lansoprazole—CYP1A1—kidney cancer	0.00139	0.653	CrCbGaD
Thiabendazole—Lansoprazole—ABCB1—kidney cancer	0.000741	0.347	CrCbGaD
Thiabendazole—Pruritus—Temsirolimus—kidney cancer	0.000468	0.00339	CcSEcCtD
Thiabendazole—Angioedema—Sunitinib—kidney cancer	0.00046	0.00334	CcSEcCtD
Thiabendazole—Hypotension—Everolimus—kidney cancer	0.00046	0.00333	CcSEcCtD
Thiabendazole—Diarrhoea—Temsirolimus—kidney cancer	0.000453	0.00328	CcSEcCtD
Thiabendazole—Anorexia—Erlotinib—kidney cancer	0.000453	0.00328	CcSEcCtD
Thiabendazole—Leukopenia—Sunitinib—kidney cancer	0.000451	0.00327	CcSEcCtD
Thiabendazole—Asthenia—Pazopanib—kidney cancer	0.000447	0.00324	CcSEcCtD
Thiabendazole—Pruritus—Pazopanib—kidney cancer	0.000441	0.0032	CcSEcCtD
Thiabendazole—Erythema multiforme—Gemcitabine—kidney cancer	0.000439	0.00318	CcSEcCtD
Thiabendazole—Hyperglycaemia—Paclitaxel—kidney cancer	0.000438	0.00318	CcSEcCtD
Thiabendazole—Somnolence—Everolimus—kidney cancer	0.000437	0.00317	CcSEcCtD
Thiabendazole—Dizziness—Temsirolimus—kidney cancer	0.000437	0.00317	CcSEcCtD
Thiabendazole—Convulsion—Sunitinib—kidney cancer	0.000436	0.00316	CcSEcCtD
Thiabendazole—Dyspepsia—Everolimus—kidney cancer	0.000433	0.00314	CcSEcCtD
Thiabendazole—Decreased appetite—Vinblastine—kidney cancer	0.000429	0.00311	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Paclitaxel—kidney cancer	0.000429	0.00311	CcSEcCtD
Thiabendazole—Decreased appetite—Everolimus—kidney cancer	0.000428	0.0031	CcSEcCtD
Thiabendazole—Anaphylactic shock—Sorafenib—kidney cancer	0.000427	0.0031	CcSEcCtD
Thiabendazole—Leukopenia—Dactinomycin—kidney cancer	0.000427	0.00309	CcSEcCtD
Thiabendazole—Diarrhoea—Pazopanib—kidney cancer	0.000426	0.00309	CcSEcCtD
Thiabendazole—Fatigue—Everolimus—kidney cancer	0.000424	0.00308	CcSEcCtD
Thiabendazole—Vomiting—Temsirolimus—kidney cancer	0.000421	0.00305	CcSEcCtD
Thiabendazole—Dyspepsia—Erlotinib—kidney cancer	0.000418	0.00303	CcSEcCtD
Thiabendazole—Rash—Temsirolimus—kidney cancer	0.000417	0.00302	CcSEcCtD
Thiabendazole—Coordination abnormal—Doxorubicin—kidney cancer	0.000417	0.00302	CcSEcCtD
Thiabendazole—Dermatitis—Temsirolimus—kidney cancer	0.000417	0.00302	CcSEcCtD
Thiabendazole—Chills—Gemcitabine—kidney cancer	0.000417	0.00302	CcSEcCtD
Thiabendazole—Headache—Temsirolimus—kidney cancer	0.000414	0.003	CcSEcCtD
Thiabendazole—Haematuria—Paclitaxel—kidney cancer	0.000413	0.00299	CcSEcCtD
Thiabendazole—Decreased appetite—Erlotinib—kidney cancer	0.000413	0.00299	CcSEcCtD
Thiabendazole—Dizziness—Pazopanib—kidney cancer	0.000412	0.00299	CcSEcCtD
Thiabendazole—Hepatocellular injury—Doxorubicin—kidney cancer	0.000409	0.00297	CcSEcCtD
Thiabendazole—Fatigue—Erlotinib—kidney cancer	0.000409	0.00297	CcSEcCtD
Thiabendazole—Anorexia—Sorafenib—kidney cancer	0.000407	0.00295	CcSEcCtD
Thiabendazole—Feeling abnormal—Vinblastine—kidney cancer	0.000407	0.00295	CcSEcCtD
Thiabendazole—Feeling abnormal—Everolimus—kidney cancer	0.000406	0.00294	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Vinblastine—kidney cancer	0.000404	0.00293	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Everolimus—kidney cancer	0.000402	0.00292	CcSEcCtD
Thiabendazole—Vomiting—Pazopanib—kidney cancer	0.000396	0.00287	CcSEcCtD
Thiabendazole—Rash—Pazopanib—kidney cancer	0.000393	0.00285	CcSEcCtD
Thiabendazole—Nausea—Temsirolimus—kidney cancer	0.000393	0.00285	CcSEcCtD
Thiabendazole—Dermatitis—Pazopanib—kidney cancer	0.000393	0.00285	CcSEcCtD
Thiabendazole—Anorexia—Sunitinib—kidney cancer	0.000392	0.00284	CcSEcCtD
Thiabendazole—Abdominal pain—Vinblastine—kidney cancer	0.000391	0.00283	CcSEcCtD
Thiabendazole—Headache—Pazopanib—kidney cancer	0.00039	0.00283	CcSEcCtD
Thiabendazole—Abdominal pain—Everolimus—kidney cancer	0.000389	0.00282	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Erlotinib—kidney cancer	0.000388	0.00281	CcSEcCtD
Thiabendazole—Hypoaesthesia—Paclitaxel—kidney cancer	0.000387	0.0028	CcSEcCtD
Thiabendazole—Leukopenia—Vincristine—kidney cancer	0.000381	0.00276	CcSEcCtD
Thiabendazole—Dyspepsia—Sorafenib—kidney cancer	0.000376	0.00273	CcSEcCtD
Thiabendazole—Abdominal pain—Erlotinib—kidney cancer	0.000375	0.00272	CcSEcCtD
Thiabendazole—Visual impairment—Paclitaxel—kidney cancer	0.000375	0.00272	CcSEcCtD
Thiabendazole—Decreased appetite—Sorafenib—kidney cancer	0.000371	0.00269	CcSEcCtD
Thiabendazole—Anorexia—Dactinomycin—kidney cancer	0.000371	0.00269	CcSEcCtD
Thiabendazole—Nausea—Pazopanib—kidney cancer	0.00037	0.00268	CcSEcCtD
Thiabendazole—Convulsion—Vincristine—kidney cancer	0.000369	0.00268	CcSEcCtD
Thiabendazole—Fatigue—Sorafenib—kidney cancer	0.000368	0.00267	CcSEcCtD
Thiabendazole—Erythema multiforme—Paclitaxel—kidney cancer	0.000367	0.00266	CcSEcCtD
Thiabendazole—Hypersensitivity—Vinblastine—kidney cancer	0.000364	0.00264	CcSEcCtD
Thiabendazole—Hypersensitivity—Everolimus—kidney cancer	0.000363	0.00263	CcSEcCtD
Thiabendazole—Tinnitus—Paclitaxel—kidney cancer	0.000362	0.00263	CcSEcCtD
Thiabendazole—Dyspepsia—Sunitinib—kidney cancer	0.000362	0.00262	CcSEcCtD
Thiabendazole—Leukopenia—Gemcitabine—kidney cancer	0.000362	0.00262	CcSEcCtD
Thiabendazole—Flushing—Paclitaxel—kidney cancer	0.000361	0.00262	CcSEcCtD
Thiabendazole—Hyperglycaemia—Capecitabine—kidney cancer	0.000359	0.00261	CcSEcCtD
Thiabendazole—Decreased appetite—Sunitinib—kidney cancer	0.000357	0.00259	CcSEcCtD
Thiabendazole—Asthenia—Vinblastine—kidney cancer	0.000354	0.00257	CcSEcCtD
Thiabendazole—Fatigue—Sunitinib—kidney cancer	0.000354	0.00257	CcSEcCtD
Thiabendazole—Asthenia—Everolimus—kidney cancer	0.000353	0.00256	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000352	0.00255	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Sorafenib—kidney cancer	0.000349	0.00253	CcSEcCtD
Thiabendazole—Chills—Paclitaxel—kidney cancer	0.000349	0.00253	CcSEcCtD
Thiabendazole—Lymphadenopathy—Doxorubicin—kidney cancer	0.000348	0.00253	CcSEcCtD
Thiabendazole—Pruritus—Everolimus—kidney cancer	0.000348	0.00252	CcSEcCtD
Thiabendazole—Anaphylactic shock—Vincristine—kidney cancer	0.000348	0.00252	CcSEcCtD
Thiabendazole—Jaundice—Capecitabine—kidney cancer	0.000346	0.00251	CcSEcCtD
Thiabendazole—Asthenia—Erlotinib—kidney cancer	0.000341	0.00247	CcSEcCtD
Thiabendazole—Haematuria—Capecitabine—kidney cancer	0.000339	0.00246	CcSEcCtD
Thiabendazole—Decreased appetite—Dactinomycin—kidney cancer	0.000338	0.00245	CcSEcCtD
Thiabendazole—Diarrhoea—Vinblastine—kidney cancer	0.000338	0.00245	CcSEcCtD
Thiabendazole—Abdominal pain—Sorafenib—kidney cancer	0.000338	0.00245	CcSEcCtD
Thiabendazole—Diarrhoea—Everolimus—kidney cancer	0.000337	0.00244	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Sunitinib—kidney cancer	0.000336	0.00244	CcSEcCtD
Thiabendazole—Pruritus—Erlotinib—kidney cancer	0.000336	0.00244	CcSEcCtD
Thiabendazole—Fatigue—Dactinomycin—kidney cancer	0.000335	0.00243	CcSEcCtD
Thiabendazole—Anorexia—Vincristine—kidney cancer	0.000331	0.0024	CcSEcCtD
Thiabendazole—Hepatic failure—Doxorubicin—kidney cancer	0.000331	0.0024	CcSEcCtD
Thiabendazole—Anaphylactic shock—Gemcitabine—kidney cancer	0.00033	0.00239	CcSEcCtD
Thiabendazole—Dizziness—Vinblastine—kidney cancer	0.000327	0.00237	CcSEcCtD
Thiabendazole—Dizziness—Everolimus—kidney cancer	0.000325	0.00236	CcSEcCtD
Thiabendazole—Abdominal pain—Sunitinib—kidney cancer	0.000325	0.00236	CcSEcCtD
Thiabendazole—Diarrhoea—Erlotinib—kidney cancer	0.000325	0.00236	CcSEcCtD
Thiabendazole—Hypotension—Vincristine—kidney cancer	0.000325	0.00236	CcSEcCtD
Thiabendazole—Feeling abnormal—Dactinomycin—kidney cancer	0.000321	0.00232	CcSEcCtD
Thiabendazole—Vision blurred—Paclitaxel—kidney cancer	0.000319	0.00231	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000318	0.00231	CcSEcCtD
Thiabendazole—Hypoaesthesia—Capecitabine—kidney cancer	0.000317	0.0023	CcSEcCtD
Thiabendazole—Hypersensitivity—Sorafenib—kidney cancer	0.000315	0.00228	CcSEcCtD
Thiabendazole—Anorexia—Gemcitabine—kidney cancer	0.000314	0.00228	CcSEcCtD
Thiabendazole—Vomiting—Vinblastine—kidney cancer	0.000314	0.00228	CcSEcCtD
Thiabendazole—Dizziness—Erlotinib—kidney cancer	0.000314	0.00228	CcSEcCtD
Thiabendazole—Vomiting—Everolimus—kidney cancer	0.000313	0.00227	CcSEcCtD
Thiabendazole—Rash—Everolimus—kidney cancer	0.00031	0.00225	CcSEcCtD
Thiabendazole—Dermatitis—Everolimus—kidney cancer	0.00031	0.00225	CcSEcCtD
Thiabendazole—Headache—Vinblastine—kidney cancer	0.000309	0.00224	CcSEcCtD
Thiabendazole—Angioedema—Paclitaxel—kidney cancer	0.000309	0.00224	CcSEcCtD
Thiabendazole—Headache—Everolimus—kidney cancer	0.000308	0.00224	CcSEcCtD
Thiabendazole—Hypotension—Gemcitabine—kidney cancer	0.000308	0.00223	CcSEcCtD
Thiabendazole—Abdominal pain—Dactinomycin—kidney cancer	0.000308	0.00223	CcSEcCtD
Thiabendazole—Visual impairment—Capecitabine—kidney cancer	0.000307	0.00223	CcSEcCtD
Thiabendazole—Asthenia—Sorafenib—kidney cancer	0.000306	0.00222	CcSEcCtD
Thiabendazole—Leukopenia—Paclitaxel—kidney cancer	0.000303	0.0022	CcSEcCtD
Thiabendazole—Hypersensitivity—Sunitinib—kidney cancer	0.000303	0.0022	CcSEcCtD
Thiabendazole—Decreased appetite—Vincristine—kidney cancer	0.000302	0.00219	CcSEcCtD
Thiabendazole—Pruritus—Sorafenib—kidney cancer	0.000302	0.00219	CcSEcCtD
Thiabendazole—Vomiting—Erlotinib—kidney cancer	0.000302	0.00219	CcSEcCtD
Thiabendazole—Erythema multiforme—Capecitabine—kidney cancer	0.000302	0.00219	CcSEcCtD
Thiabendazole—Fatigue—Vincristine—kidney cancer	0.0003	0.00217	CcSEcCtD
Thiabendazole—Rash—Erlotinib—kidney cancer	0.000299	0.00217	CcSEcCtD
Thiabendazole—Dermatitis—Erlotinib—kidney cancer	0.000299	0.00217	CcSEcCtD
Thiabendazole—Headache—Erlotinib—kidney cancer	0.000297	0.00216	CcSEcCtD
Thiabendazole—Tinnitus—Capecitabine—kidney cancer	0.000297	0.00216	CcSEcCtD
Thiabendazole—Flushing—Capecitabine—kidney cancer	0.000296	0.00215	CcSEcCtD
Thiabendazole—Asthenia—Sunitinib—kidney cancer	0.000295	0.00214	CcSEcCtD
Thiabendazole—Nausea—Vinblastine—kidney cancer	0.000293	0.00213	CcSEcCtD
Thiabendazole—Somnolence—Gemcitabine—kidney cancer	0.000293	0.00213	CcSEcCtD
Thiabendazole—Convulsion—Paclitaxel—kidney cancer	0.000293	0.00213	CcSEcCtD
Thiabendazole—Nausea—Everolimus—kidney cancer	0.000292	0.00212	CcSEcCtD
Thiabendazole—Diarrhoea—Sorafenib—kidney cancer	0.000292	0.00212	CcSEcCtD
Thiabendazole—Pruritus—Sunitinib—kidney cancer	0.000291	0.00211	CcSEcCtD
Thiabendazole—Decreased appetite—Gemcitabine—kidney cancer	0.000287	0.00208	CcSEcCtD
Thiabendazole—Hypersensitivity—Dactinomycin—kidney cancer	0.000287	0.00208	CcSEcCtD
Thiabendazole—Chills—Capecitabine—kidney cancer	0.000286	0.00207	CcSEcCtD
Thiabendazole—Fatigue—Gemcitabine—kidney cancer	0.000284	0.00206	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Vincristine—kidney cancer	0.000284	0.00206	CcSEcCtD
Thiabendazole—Dizziness—Sorafenib—kidney cancer	0.000282	0.00205	CcSEcCtD
Thiabendazole—Nausea—Erlotinib—kidney cancer	0.000282	0.00204	CcSEcCtD
Thiabendazole—Diarrhoea—Sunitinib—kidney cancer	0.000281	0.00204	CcSEcCtD
Thiabendazole—Asthenia—Dactinomycin—kidney cancer	0.000279	0.00202	CcSEcCtD
Thiabendazole—Confusional state—Paclitaxel—kidney cancer	0.000278	0.00202	CcSEcCtD
Thiabendazole—Anaphylactic shock—Paclitaxel—kidney cancer	0.000276	0.002	CcSEcCtD
Thiabendazole—Abdominal pain—Vincristine—kidney cancer	0.000275	0.00199	CcSEcCtD
Thiabendazole—Dizziness—Sunitinib—kidney cancer	0.000272	0.00197	CcSEcCtD
Thiabendazole—Feeling abnormal—Gemcitabine—kidney cancer	0.000272	0.00197	CcSEcCtD
Thiabendazole—Vomiting—Sorafenib—kidney cancer	0.000272	0.00197	CcSEcCtD
Thiabendazole—Rash—Sorafenib—kidney cancer	0.000269	0.00195	CcSEcCtD
Thiabendazole—Dermatitis—Sorafenib—kidney cancer	0.000269	0.00195	CcSEcCtD
Thiabendazole—Headache—Sorafenib—kidney cancer	0.000268	0.00194	CcSEcCtD
Thiabendazole—Diarrhoea—Dactinomycin—kidney cancer	0.000266	0.00193	CcSEcCtD
Thiabendazole—Anorexia—Paclitaxel—kidney cancer	0.000263	0.00191	CcSEcCtD
Thiabendazole—Vision blurred—Capecitabine—kidney cancer	0.000262	0.0019	CcSEcCtD
Thiabendazole—Vomiting—Sunitinib—kidney cancer	0.000261	0.00189	CcSEcCtD
Thiabendazole—Rash—Sunitinib—kidney cancer	0.000259	0.00188	CcSEcCtD
Thiabendazole—Dermatitis—Sunitinib—kidney cancer	0.000259	0.00188	CcSEcCtD
Thiabendazole—Hypotension—Paclitaxel—kidney cancer	0.000258	0.00187	CcSEcCtD
Thiabendazole—Headache—Sunitinib—kidney cancer	0.000257	0.00187	CcSEcCtD
Thiabendazole—Hypersensitivity—Vincristine—kidney cancer	0.000256	0.00186	CcSEcCtD
Thiabendazole—Nausea—Sorafenib—kidney cancer	0.000254	0.00184	CcSEcCtD
Thiabendazole—Asthenia—Vincristine—kidney cancer	0.000249	0.00181	CcSEcCtD
Thiabendazole—Leukopenia—Capecitabine—kidney cancer	0.000249	0.0018	CcSEcCtD
Thiabendazole—Vomiting—Dactinomycin—kidney cancer	0.000247	0.00179	CcSEcCtD
Thiabendazole—Somnolence—Paclitaxel—kidney cancer	0.000245	0.00178	CcSEcCtD
Thiabendazole—Rash—Dactinomycin—kidney cancer	0.000245	0.00178	CcSEcCtD
Thiabendazole—Nausea—Sunitinib—kidney cancer	0.000244	0.00177	CcSEcCtD
Thiabendazole—Dyspepsia—Paclitaxel—kidney cancer	0.000243	0.00176	CcSEcCtD
Thiabendazole—Decreased appetite—Paclitaxel—kidney cancer	0.00024	0.00174	CcSEcCtD
Thiabendazole—Fatigue—Paclitaxel—kidney cancer	0.000238	0.00173	CcSEcCtD
Thiabendazole—Diarrhoea—Vincristine—kidney cancer	0.000238	0.00172	CcSEcCtD
Thiabendazole—Asthenia—Gemcitabine—kidney cancer	0.000237	0.00172	CcSEcCtD
Thiabendazole—Pruritus—Gemcitabine—kidney cancer	0.000233	0.00169	CcSEcCtD
Thiabendazole—Hyperglycaemia—Doxorubicin—kidney cancer	0.000232	0.00168	CcSEcCtD
Thiabendazole—Nausea—Dactinomycin—kidney cancer	0.000231	0.00168	CcSEcCtD
Thiabendazole—Dizziness—Vincristine—kidney cancer	0.00023	0.00167	CcSEcCtD
Thiabendazole—Drowsiness—Doxorubicin—kidney cancer	0.000229	0.00166	CcSEcCtD
Thiabendazole—Confusional state—Capecitabine—kidney cancer	0.000228	0.00166	CcSEcCtD
Thiabendazole—Feeling abnormal—Paclitaxel—kidney cancer	0.000228	0.00165	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000227	0.00165	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000226	0.00164	CcSEcCtD
Thiabendazole—Diarrhoea—Gemcitabine—kidney cancer	0.000226	0.00164	CcSEcCtD
Thiabendazole—Jaundice—Doxorubicin—kidney cancer	0.000223	0.00162	CcSEcCtD
Thiabendazole—Vomiting—Vincristine—kidney cancer	0.000221	0.0016	CcSEcCtD
Thiabendazole—Rash—Vincristine—kidney cancer	0.000219	0.00159	CcSEcCtD
Thiabendazole—Dermatitis—Vincristine—kidney cancer	0.000219	0.00159	CcSEcCtD
Thiabendazole—Haematuria—Doxorubicin—kidney cancer	0.000218	0.00158	CcSEcCtD
Thiabendazole—Abdominal pain—Paclitaxel—kidney cancer	0.000218	0.00158	CcSEcCtD
Thiabendazole—Headache—Vincristine—kidney cancer	0.000218	0.00158	CcSEcCtD
Thiabendazole—Anorexia—Capecitabine—kidney cancer	0.000216	0.00157	CcSEcCtD
Thiabendazole—Hypotension—Capecitabine—kidney cancer	0.000212	0.00154	CcSEcCtD
Thiabendazole—Vomiting—Gemcitabine—kidney cancer	0.00021	0.00152	CcSEcCtD
Thiabendazole—Rash—Gemcitabine—kidney cancer	0.000208	0.00151	CcSEcCtD
Thiabendazole—Dermatitis—Gemcitabine—kidney cancer	0.000208	0.00151	CcSEcCtD
Thiabendazole—Headache—Gemcitabine—kidney cancer	0.000207	0.0015	CcSEcCtD
Thiabendazole—Nausea—Vincristine—kidney cancer	0.000207	0.0015	CcSEcCtD
Thiabendazole—Hypoaesthesia—Doxorubicin—kidney cancer	0.000205	0.00148	CcSEcCtD
Thiabendazole—Hypersensitivity—Paclitaxel—kidney cancer	0.000203	0.00147	CcSEcCtD
Thiabendazole—Dyspepsia—Capecitabine—kidney cancer	0.000199	0.00145	CcSEcCtD
Thiabendazole—Visual impairment—Doxorubicin—kidney cancer	0.000198	0.00144	CcSEcCtD
Thiabendazole—Asthenia—Paclitaxel—kidney cancer	0.000198	0.00144	CcSEcCtD
Thiabendazole—Decreased appetite—Capecitabine—kidney cancer	0.000197	0.00143	CcSEcCtD
Thiabendazole—Nausea—Gemcitabine—kidney cancer	0.000196	0.00142	CcSEcCtD
Thiabendazole—Fatigue—Capecitabine—kidney cancer	0.000195	0.00142	CcSEcCtD
Thiabendazole—Pruritus—Paclitaxel—kidney cancer	0.000195	0.00142	CcSEcCtD
Thiabendazole—Erythema multiforme—Doxorubicin—kidney cancer	0.000194	0.00141	CcSEcCtD
Thiabendazole—Tinnitus—Doxorubicin—kidney cancer	0.000192	0.00139	CcSEcCtD
Thiabendazole—Flushing—Doxorubicin—kidney cancer	0.000191	0.00138	CcSEcCtD
Thiabendazole—Diarrhoea—Paclitaxel—kidney cancer	0.000189	0.00137	CcSEcCtD
Thiabendazole—Feeling abnormal—Capecitabine—kidney cancer	0.000187	0.00135	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Capecitabine—kidney cancer	0.000185	0.00134	CcSEcCtD
Thiabendazole—Chills—Doxorubicin—kidney cancer	0.000184	0.00134	CcSEcCtD
Thiabendazole—Dizziness—Paclitaxel—kidney cancer	0.000183	0.00132	CcSEcCtD
Thiabendazole—Abdominal pain—Capecitabine—kidney cancer	0.000179	0.0013	CcSEcCtD
Thiabendazole—Vomiting—Paclitaxel—kidney cancer	0.000176	0.00127	CcSEcCtD
Thiabendazole—Rash—Paclitaxel—kidney cancer	0.000174	0.00126	CcSEcCtD
Thiabendazole—Dermatitis—Paclitaxel—kidney cancer	0.000174	0.00126	CcSEcCtD
Thiabendazole—Headache—Paclitaxel—kidney cancer	0.000173	0.00125	CcSEcCtD
Thiabendazole—Vision blurred—Doxorubicin—kidney cancer	0.000169	0.00122	CcSEcCtD
Thiabendazole—Hypersensitivity—Capecitabine—kidney cancer	0.000167	0.00121	CcSEcCtD
Thiabendazole—Nausea—Paclitaxel—kidney cancer	0.000164	0.00119	CcSEcCtD
Thiabendazole—Asthenia—Capecitabine—kidney cancer	0.000163	0.00118	CcSEcCtD
Thiabendazole—Pruritus—Capecitabine—kidney cancer	0.00016	0.00116	CcSEcCtD
Thiabendazole—Leukopenia—Doxorubicin—kidney cancer	0.00016	0.00116	CcSEcCtD
Thiabendazole—Convulsion—Doxorubicin—kidney cancer	0.000155	0.00112	CcSEcCtD
Thiabendazole—Diarrhoea—Capecitabine—kidney cancer	0.000155	0.00112	CcSEcCtD
Thiabendazole—Dizziness—Capecitabine—kidney cancer	0.00015	0.00109	CcSEcCtD
Thiabendazole—Confusional state—Doxorubicin—kidney cancer	0.000147	0.00107	CcSEcCtD
Thiabendazole—Anaphylactic shock—Doxorubicin—kidney cancer	0.000146	0.00106	CcSEcCtD
Thiabendazole—Vomiting—Capecitabine—kidney cancer	0.000144	0.00104	CcSEcCtD
Thiabendazole—Rash—Capecitabine—kidney cancer	0.000143	0.00104	CcSEcCtD
Thiabendazole—Dermatitis—Capecitabine—kidney cancer	0.000143	0.00103	CcSEcCtD
Thiabendazole—Headache—Capecitabine—kidney cancer	0.000142	0.00103	CcSEcCtD
Thiabendazole—CYP1A2—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000141	0.0617	CbGpPWpGaD
Thiabendazole—Anorexia—Doxorubicin—kidney cancer	0.000139	0.00101	CcSEcCtD
Thiabendazole—CYP1A1—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000139	0.0608	CbGpPWpGaD
Thiabendazole—Hypotension—Doxorubicin—kidney cancer	0.000136	0.00099	CcSEcCtD
Thiabendazole—Nausea—Capecitabine—kidney cancer	0.000135	0.000976	CcSEcCtD
Thiabendazole—Somnolence—Doxorubicin—kidney cancer	0.00013	0.000941	CcSEcCtD
Thiabendazole—Dyspepsia—Doxorubicin—kidney cancer	0.000129	0.000932	CcSEcCtD
Thiabendazole—Decreased appetite—Doxorubicin—kidney cancer	0.000127	0.000921	CcSEcCtD
Thiabendazole—Fatigue—Doxorubicin—kidney cancer	0.000126	0.000913	CcSEcCtD
Thiabendazole—Feeling abnormal—Doxorubicin—kidney cancer	0.00012	0.000873	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000119	0.000866	CcSEcCtD
Thiabendazole—Abdominal pain—Doxorubicin—kidney cancer	0.000115	0.000837	CcSEcCtD
Thiabendazole—Hypersensitivity—Doxorubicin—kidney cancer	0.000108	0.00078	CcSEcCtD
Thiabendazole—Asthenia—Doxorubicin—kidney cancer	0.000105	0.00076	CcSEcCtD
Thiabendazole—Pruritus—Doxorubicin—kidney cancer	0.000103	0.000749	CcSEcCtD
Thiabendazole—Diarrhoea—Doxorubicin—kidney cancer	9.99e-05	0.000725	CcSEcCtD
Thiabendazole—Dizziness—Doxorubicin—kidney cancer	9.66e-05	0.0007	CcSEcCtD
Thiabendazole—Vomiting—Doxorubicin—kidney cancer	9.29e-05	0.000673	CcSEcCtD
Thiabendazole—Rash—Doxorubicin—kidney cancer	9.21e-05	0.000668	CcSEcCtD
Thiabendazole—Dermatitis—Doxorubicin—kidney cancer	9.2e-05	0.000667	CcSEcCtD
Thiabendazole—Headache—Doxorubicin—kidney cancer	9.15e-05	0.000663	CcSEcCtD
Thiabendazole—CYP1A2—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	8.86e-05	0.0388	CbGpPWpGaD
Thiabendazole—Nausea—Doxorubicin—kidney cancer	8.68e-05	0.000629	CcSEcCtD
Thiabendazole—CYP1A2—Aflatoxin B1 metabolism—GSTM1—kidney cancer	6.43e-05	0.0281	CbGpPWpGaD
Thiabendazole—CYP1A1—Tryptophan metabolism—ALDH1A1—kidney cancer	5.97e-05	0.0261	CbGpPWpGaD
Thiabendazole—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	5.47e-05	0.024	CbGpPWpGaD
Thiabendazole—CYP1A1—Melatonin metabolism and effects—ACHE—kidney cancer	5.07e-05	0.0222	CbGpPWpGaD
Thiabendazole—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	4.98e-05	0.0218	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen metabolism—GSTM1—kidney cancer	4.73e-05	0.0207	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	4.25e-05	0.0186	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidative Stress—JUNB—kidney cancer	4.07e-05	0.0178	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	3.91e-05	0.0171	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—ALDH1A1—kidney cancer	3.81e-05	0.0167	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—ACY1—kidney cancer	3.79e-05	0.0166	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—GLIPR1—kidney cancer	3.76e-05	0.0165	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—CYP1A1—kidney cancer	3.71e-05	0.0162	CbGpPWpGaD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—GLIPR1—kidney cancer	3.68e-05	0.0161	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—ACHE—kidney cancer	3.24e-05	0.0142	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidative Stress—SOD2—kidney cancer	3.16e-05	0.0138	CbGpPWpGaD
Thiabendazole—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	3.14e-05	0.0138	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—JUN—kidney cancer	3.12e-05	0.0137	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—PTGS1—kidney cancer	3.08e-05	0.0135	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—GSTM1—kidney cancer	3.02e-05	0.0132	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	2.89e-05	0.0127	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—CYP1A1—kidney cancer	2.86e-05	0.0125	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	2.71e-05	0.0119	CbGpPWpGaD
Thiabendazole—CYP1A2—Xenobiotics—CYP1A1—kidney cancer	2.63e-05	0.0115	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—GLIPR1—kidney cancer	2.54e-05	0.0111	CbGpPWpGaD
Thiabendazole—CYP1A2—Tamoxifen metabolism—CYP1A1—kidney cancer	2.53e-05	0.0111	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	2.49e-05	0.0109	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—ACY1—kidney cancer	2.42e-05	0.0106	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2.15e-05	0.00943	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—ALDH1A1—kidney cancer	2.08e-05	0.0091	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—JUN—kidney cancer	1.99e-05	0.00871	CbGpPWpGaD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—PTGS1—kidney cancer	1.96e-05	0.00858	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—CYP1A1—kidney cancer	1.95e-05	0.00855	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	1.87e-05	0.00818	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	1.85e-05	0.00808	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—kidney cancer	1.39e-05	0.00608	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	1.37e-05	0.00601	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	1.35e-05	0.00591	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	1.35e-05	0.00591	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	1.35e-05	0.00591	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	1.33e-05	0.00583	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	1.33e-05	0.0058	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	1.3e-05	0.0057	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—RELA—kidney cancer	1.3e-05	0.00568	CbGpPWpGaD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.28e-05	0.00559	CbGpPWpGaD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	1.26e-05	0.00553	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	1.26e-05	0.00551	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTT1—kidney cancer	1.22e-05	0.00535	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	1.19e-05	0.00522	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	1.19e-05	0.00522	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—PTGS2—kidney cancer	1.18e-05	0.00516	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	1.17e-05	0.00511	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—PTGS1—kidney cancer	1.14e-05	0.00501	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	1.14e-05	0.00497	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	1.09e-05	0.00478	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	1.08e-05	0.00472	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.04e-05	0.00453	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	1.01e-05	0.00442	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	9.92e-06	0.00434	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	9.23e-06	0.00404	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—kidney cancer	9.13e-06	0.004	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	8.93e-06	0.00391	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	8.85e-06	0.00388	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	8.48e-06	0.00371	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTP1—kidney cancer	8.47e-06	0.00371	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	8.44e-06	0.00369	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTP1—kidney cancer	8.35e-06	0.00366	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	8.3e-06	0.00363	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	8.27e-06	0.00362	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.14e-06	0.00356	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	8.03e-06	0.00352	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTT1—kidney cancer	7.79e-06	0.00341	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTM1—kidney cancer	7.78e-06	0.00341	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTM1—kidney cancer	7.67e-06	0.00336	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	7.61e-06	0.00333	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	7.61e-06	0.00333	CbGpPWpGaD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	7.51e-06	0.00329	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	7.44e-06	0.00326	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—PTGS1—kidney cancer	7.3e-06	0.00319	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	7.24e-06	0.00317	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.6e-06	0.00289	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ACY1—kidney cancer	6.49e-06	0.00284	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	6.44e-06	0.00282	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	6.33e-06	0.00277	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	5.82e-06	0.00255	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	5.7e-06	0.00249	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.53e-06	0.00242	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PDHB—kidney cancer	5.52e-06	0.00241	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—POMC—kidney cancer	5.5e-06	0.00241	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTP1—kidney cancer	5.4e-06	0.00236	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	5.38e-06	0.00235	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	5.32e-06	0.00233	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CCBL1—kidney cancer	5.19e-06	0.00227	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTM1—kidney cancer	4.96e-06	0.00217	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	4.89e-06	0.00214	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	4.7e-06	0.00206	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.69e-06	0.00205	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	4.64e-06	0.00203	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GLIPR1—kidney cancer	4.5e-06	0.00197	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PPAT—kidney cancer	4.5e-06	0.00197	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.44e-06	0.00194	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.4e-06	0.00192	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—FH—kidney cancer	4.18e-06	0.00183	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—APRT—kidney cancer	4.18e-06	0.00183	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ACY1—kidney cancer	4.14e-06	0.00181	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.09e-06	0.00179	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GPC3—kidney cancer	3.93e-06	0.00172	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CA2—kidney cancer	3.82e-06	0.00167	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ALAD—kidney cancer	3.73e-06	0.00163	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ST3GAL2—kidney cancer	3.64e-06	0.00159	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ALDH1A1—kidney cancer	3.55e-06	0.00156	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.53e-06	0.00154	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PDHB—kidney cancer	3.52e-06	0.00154	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—POMC—kidney cancer	3.51e-06	0.00153	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PGK1—kidney cancer	3.41e-06	0.00149	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SLC5A3—kidney cancer	3.41e-06	0.00149	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—LDHB—kidney cancer	3.34e-06	0.00146	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CCBL1—kidney cancer	3.31e-06	0.00145	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.99e-06	0.00131	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CA9—kidney cancer	2.9e-06	0.00127	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PPAT—kidney cancer	2.87e-06	0.00126	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.87e-06	0.00126	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.83e-06	0.00124	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.8e-06	0.00123	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—APRT—kidney cancer	2.67e-06	0.00117	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—FH—kidney cancer	2.67e-06	0.00117	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.61e-06	0.00114	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GPC3—kidney cancer	2.51e-06	0.0011	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CRABP1—kidney cancer	2.46e-06	0.00108	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CA2—kidney cancer	2.44e-06	0.00107	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ALAD—kidney cancer	2.38e-06	0.00104	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ST3GAL2—kidney cancer	2.32e-06	0.00102	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ITPR2—kidney cancer	2.29e-06	0.001	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ALDH1A1—kidney cancer	2.27e-06	0.000992	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PGK1—kidney cancer	2.17e-06	0.000951	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SLC5A3—kidney cancer	2.17e-06	0.000951	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—LDHB—kidney cancer	2.13e-06	0.000933	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.11e-06	0.000924	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ACHE—kidney cancer	2.09e-06	0.000914	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTT1—kidney cancer	2.09e-06	0.000914	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SCARB1—kidney cancer	1.98e-06	0.000866	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTGS1—kidney cancer	1.96e-06	0.000857	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PSMD7—kidney cancer	1.92e-06	0.00084	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CA9—kidney cancer	1.85e-06	0.000809	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—BCHE—kidney cancer	1.82e-06	0.000797	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.81e-06	0.00079	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SLC5A5—kidney cancer	1.8e-06	0.000787	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SLC2A1—kidney cancer	1.74e-06	0.00076	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.68e-06	0.000737	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CRABP1—kidney cancer	1.57e-06	0.000688	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.47e-06	0.000643	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ITPR2—kidney cancer	1.46e-06	0.000639	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTP1—kidney cancer	1.45e-06	0.000634	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ABCB1—kidney cancer	1.37e-06	0.0006	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.35e-06	0.000589	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ACHE—kidney cancer	1.33e-06	0.000583	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTT1—kidney cancer	1.33e-06	0.000583	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTM1—kidney cancer	1.33e-06	0.000582	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SCARB1—kidney cancer	1.26e-06	0.000552	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTGS1—kidney cancer	1.25e-06	0.000546	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PSMD7—kidney cancer	1.22e-06	0.000536	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—BCHE—kidney cancer	1.16e-06	0.000508	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.15e-06	0.000502	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.11e-06	0.000485	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.07e-06	0.00047	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.04e-06	0.000454	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—POMC—kidney cancer	9.4e-07	0.000412	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.37e-07	0.00041	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTP1—kidney cancer	9.23e-07	0.000404	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ABCB1—kidney cancer	8.74e-07	0.000383	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTM1—kidney cancer	8.48e-07	0.000371	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP1A1—kidney cancer	8.04e-07	0.000352	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTGS2—kidney cancer	7.5e-07	0.000328	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.61e-07	0.000289	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTEN—kidney cancer	6.54e-07	0.000286	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—POMC—kidney cancer	6e-07	0.000262	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTGS2—kidney cancer	4.78e-07	0.000209	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CA—kidney cancer	4.61e-07	0.000202	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTEN—kidney cancer	4.17e-07	0.000183	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.94e-07	0.000129	CbGpPWpGaD
